| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.09 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.097 | 0.09 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |